Vir Biotechnology, Inc. Debt Securities, Available-for-sale, Allowance for Credit Loss
Vir Biotechnology, Inc. (VIR) had Debt Securities, Available-for-sale, Allowance for Credit Loss of $0 as of 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Credit Losses
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss · last filed 2026-02-23
- 2025-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2024-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2023-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2023-09-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-23 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-23 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-03 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-04 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-08 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-26 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-03 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-04 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |